Abstract The invention pertains to a probiotic agent designed to modulate the gut hormone GLP-1 levels, encompassing the Lacticaseibacillus rhamnosus LRa05 strain (CGMCC No.1.12734) and its application in obesity treatment. The LRa05 strain significantly enhances GLP-1 expression in intestinal endocrine cells, reducing body weight and serum ALT and AST levels in obese individuals....

Abstract The patent describes the discovery and application of a specific strain of Limosilactobacillus reuteri (LR38), preserved under CGMCC No.24408, which is effective in improving polycystic ovary syndrome (PCOS). The strain addresses PCOS-related symptoms such as metabolic level disorders and abnormal sex hormone levels, providing a potential preventive, alleviating, or therapeutic...